Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed/Refractory Burkitt Lymphoma”

456 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 456 results

Early research (Phase 1)Not Yet RecruitingNCT07113496
What this trial is testing

RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies

Who this might be right for
Relapsed or Refractory B-cell Hematologic MalignanciesB-cell Acute Lymphoblastic Leukemia (B-ALL)Multiple Myeloma (MM)+3 more
The First Affiliated Hospital with Nanjing Medical University 27
Early research (Phase 1)Study completedNCT00005946
What this trial is testing

Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation

Who this might be right for
LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+1 more
University of Maryland, Baltimore
Early research (Phase 1)WithdrawnNCT04094766
What this trial is testing

Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia

Who this might be right for
Refractory B Acute Lymphoblastic LeukemiaRelapse B Acute Lymphoblastic Leukemia
Second Affiliated Hospital of Xi'an Jiaotong University
Early research (Phase 1)Study completedNCT00891137
What this trial is testing

Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy

Who this might be right for
LeukemiaLymphomaMultiple Myeloma+2 more
Cellerant Therapeutics 30
Early research (Phase 1)Active Not RecruitingNCT03962465
What this trial is testing

Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL

Who this might be right for
B-cell Acute Lymphoblastic Leukemia
University of Virginia 36
Early research (Phase 1)Study completedNCT00569283
What this trial is testing

Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant

Who this might be right for
Cancer
Asan Medical Center 18
Large-scale testing (Phase 3)UnknownNCT03391739
What this trial is testing

CART-19 Cells For R/R B-ALL

Who this might be right for
Relapsed/Refractory B-cell ALL
Fujian Medical University 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT02143414
What this trial is testing

Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia

Who this might be right for
Acute Lymphoblastic LeukemiaB Acute Lymphoblastic LeukemiaB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1+2 more
National Cancer Institute (NCI) 53
Testing effectiveness (Phase 2)Looking for participantsNCT02981628
What this trial is testing

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

Who this might be right for
Recurrent B Acute Lymphoblastic LeukemiaRecurrent B Lymphoblastic LymphomaRefractory B Acute Lymphoblastic Leukemia+1 more
Children's Oncology Group 80
Not applicableLooking for participantsNCT06450067
What this trial is testing

Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia

Who this might be right for
B-cell Acute Lymphoblastic Leukemia
Juventas Cell Therapy Ltd. 200
Early research (Phase 1)UnknownNCT00769613
What this trial is testing

Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections

Who this might be right for
Cancer
Milton S. Hershey Medical Center 20
Early research (Phase 1)Study completedNCT01588015
What this trial is testing

Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia in Remission+123 more
City of Hope Medical Center 36
Early research (Phase 1)Study completedNCT02950220
What this trial is testing

Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Who this might be right for
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin LymphomaGrade 1 Follicular LymphomaGrade 2 Follicular Lymphoma+16 more
Kami Maddocks 2
Testing effectiveness (Phase 2)Study completedNCT01839916
What this trial is testing

Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)+61 more
University of Chicago 77
Very early researchEnded earlyNCT04034446
What this trial is testing

CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)

Who this might be right for
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China 2
Testing effectiveness (Phase 2)UnknownNCT02134262
What this trial is testing

Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes

Who this might be right for
Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Jichi Medical University 18
Testing effectiveness (Phase 2)Active Not RecruitingNCT03793140
What this trial is testing

CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations

Who this might be right for
LymphomaLeukemia
Memorial Sloan Kettering Cancer Center 24
Very early researchUnknownNCT05105867
What this trial is testing

CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies

Who this might be right for
Relapsed or Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed or Refractory B-cell Non-hodgkin Lymphoma
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China 15
Not applicableStudy completedNCT00053157
What this trial is testing

Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia

Who this might be right for
Chronic Myeloproliferative DisordersGraft Versus Host DiseaseLeukemia+3 more
Roswell Park Cancer Institute 10
Testing effectiveness (Phase 2)WithdrawnNCT04448834
What this trial is testing

Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL

Who this might be right for
B-cell Acute Lymphoblastic Leukemia
Dorothy Sipkins, MD, PhD
Load More Results